title: Rioprostil, a new prostaglandin E1 analogue, in the once-daily treatment for the prevention of duodenal ulcer recurrence: a comparison with ranitidine.
abstract: The efficacy of Rioprostil (a new prostaglandin E1 analogue) is compared with that of ranitidine in the recurrence prevention of duodenal ulcer(s). Duration of treatment is 6 months. Ninety-seven patients received rioprostil, 600 micrograms once-daily orally, and 110 patients received ranitidine, 150 mg once-daily orally. On rioprostil, 14.9% of patients showed a relapse after 6 months compared to 10.1% on ranitidine. Diarrhoea occurred in 7 patients on rioprostil and 3 patients on ranitidine. Rioprostil given 600 micrograms daily in the evening is a highly effective treatment for the prevention of duodenal ulcer relapse, the efficacy not being significantly different from ranitidine 150 mg.
authors.affiliation: Cilag Ltd, Dept Clinical Research and Development, Schaffhausen, Switzerland.
authors.forename: J A
authors.initials: JA
authors.lastname: Businger
authors.forename: I
authors.initials: I
authors.lastname: Fumagalli
authors.forename: H
authors.initials: H
authors.lastname: Michel
authors.forename: N
authors.initials: N
authors.lastname: Delas
authors.forename: H
authors.initials: H
authors.lastname: Stocker
mesh_terms: D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011458:Prostaglandins E / Q000627:therapeutic use*; D011465:Prostaglandins, Synthetic / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011899:Ranitidine / Q000627:therapeutic use*; D012008:Recurrence; D016630:Rioprostil
chemical_list: D000897:Anti-Ulcer Agents; D011458:Prostaglandins E; D011465:Prostaglandins, Synthetic; D016630:Rioprostil; D011899:Ranitidine